These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32457865)

  • 1. Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.
    Schey C; Postma MJ; Krabbe PFM; Topachevskyi O; Volovyk A; Connolly M
    Front Public Health; 2020; 8():162. PubMed ID: 32457865
    [No Abstract]   [Full Text] [Related]  

  • 2. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).
    de Andrés-Nogales F; Cruz E; Calleja MÁ; Delgado O; Gorgas MQ; Espín J; Mestre-Ferrándiz J; Palau F; Ancochea A; Arce R; Domínguez-Hernández R; Casado MÁ;
    Orphanet J Rare Dis; 2021 Apr; 16(1):186. PubMed ID: 33902672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs.
    Schey C; Krabbe PF; Postma MJ; Connolly MP
    Orphanet J Rare Dis; 2017 Jan; 12(1):10. PubMed ID: 28095876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 5. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Front Public Health; 2016; 4():214. PubMed ID: 27747207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a value assessment framework for orphan medicinal products in China.
    Chen H; Xiang Y; Tang X; Hu M
    Orphanet J Rare Dis; 2024 Oct; 19(1):390. PubMed ID: 39428462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs.
    Alnaqbi KA; Elezbawy B; Fasseeh AN; Bangash AR; Elshamy A; Shendi H; Aftab MI; AlMarshoodi M; Gebran N; AlDhaheri N; Fahmy SA; Al Dallal S; Al Naeem W; Abaza S; Kaló Z
    Cureus; 2024 Feb; 16(2):e55215. PubMed ID: 38558740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?
    Baran-Kooiker A; Czech M; Kooiker C
    Front Public Health; 2018; 6():287. PubMed ID: 30374435
    [No Abstract]   [Full Text] [Related]  

  • 9. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).
    Guarga L; Badia X; Obach M; Fontanet M; Prat A; Vallano A; Torrent J; Pontes C
    Orphanet J Rare Dis; 2019 Jun; 14(1):157. PubMed ID: 31248421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using multi-criteria decision analysis to appraise orphan drugs: a systematic review.
    Friedmann C; Levy P; Hensel P; Hiligsmann M
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):135-146. PubMed ID: 29210308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Step Toward the Development of the First National Multi-Criteria Decision Analysis Framework to Support Healthcare Decision Making in Saudi Arabia.
    Al-Jedai A; Almudaiheem H; Alruthia Y; Althemery A; Alabdulkarim H; Ojeil R; Alrumaih A; AlGhannam S; AlMutairi A; Hasnan Z
    Value Health Reg Issues; 2024 May; 41():100-107. PubMed ID: 38306770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING.
    Roldán ÚB; Badia X; Marcos-Rodríguez JA; de la Cruz-Merino L; Gómez-González J; Melcón-de Dios A; Caraballo-Camacho MO; Cordero-Ramos J; Alvarado-Fernández MD; Galiana-Auchel JM; Calleja-Hernández MÁ
    Int J Technol Assess Health Care; 2018 Jan; 34(5):519-526. PubMed ID: 30348241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying and measuring stakeholder preferences for disease prioritisation: A case study of the pig industry in Australia.
    Brookes VJ; Hernández-Jover M; Neslo R; Cowled B; Holyoake P; Ward MP
    Prev Vet Med; 2014 Jan; 113(1):118-31. PubMed ID: 24211106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis.
    Kolasa K; Zwolinski KM; Zah V; Kaló Z; Lewandowski T
    Orphanet J Rare Dis; 2018 Apr; 13(1):67. PubMed ID: 29703227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients.
    Vu M; Degeling K; Westerman D; IJzerman MJ
    J Cancer Policy; 2024 Sep; 41():100501. PubMed ID: 39142605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework.
    Campolina AG; Estevez-Diz MDP; Abe JM; de Soárez PC
    PLoS One; 2022; 17(5):e0268584. PubMed ID: 35613115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.
    Gilabert-Perramon A; Torrent-Farnell J; Catalan A; Prat A; Fontanet M; Puig-Peiró R; Merino-Montero S; Khoury H; Goetghebeur MM; Badia X
    Int J Technol Assess Health Care; 2017 Jan; 33(1):111-120. PubMed ID: 28434413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value-based decision-making for orphan drugs with multiple criteria decision analysis: burosumab for the treatment of X-linked hypophosphatemia.
    Vandewalle B; Amorim M; Ramos D; Azevedo S; Alves I; Francisco T; Pinto H; Sousa S
    Curr Med Res Opin; 2021 Jun; 37(6):1021-1030. PubMed ID: 33733971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies.
    Dabbous O; Chachoua L; Aballéa S; Sivignon M; Persson U; Petrou S; Richardson J; Simoens S; Toumi M
    Adv Ther; 2023 Feb; 40(2):393-424. PubMed ID: 36451072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.